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IL-21 Reduces Immediate Hypersensitivity Reactions
in Mouse Skin by Suppressing Mast Cell Activation
or IgE Production
Risa Tamagawa-Mineoka1, Tsunao Kishida2, Osam Mazda2 and Norito Katoh1
IL-21 regulates activation, proliferation, and differentiation of various immune cells. We have previously shown
that exogenous IL-21 administration reduces allergic reactions in mouse models of anaphylaxis and allergic
rhinitis. However, the effects of IL-21 in allergic cutaneous reactions remain unclear. In this study, we examined
the effects of IL-21 in a mouse model of the IgE-mediated cutaneous immediate hypersensitivity reaction (IHR).
We also investigated the mechanism of IL-21-induced regulation of allergic cutaneous reactions. Mice were
sensitized by intraperitoneal ovalbumin (OVA) injection and challenged by injecting OVA intradermally into the
ears, with intraperitoneal administration of recombinant murine (rm)IL-21 during the sensitization period or
after completion of sensitization. After challenge, IL-21-untreated allergic mice developed biphasic responses
characterized by early-phase and late-phase reactions. The biphasic reactions were significantly reduced by
rmIL-21 treatment during sensitization or after completion of sensitization. Administration of rmIL-21 during
sensitization reduced the cutaneous IHR by suppressing allergen-specific IgE production. In contrast,
administration of rmIL-21 after completion of sensitization did not decrease serum levels of allergen-specific
IgE, but significantly suppressed mast cell degranulation in skin. These results suggest that the regulatory
effects of IL-21 on the cutaneous IHR involve suppression of allergen-specific IgE production or mast cell
degranulation.
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INTRODUCTION
The immediate hypersensitivity reaction (IHR) is involved in
the pathogenesis of many cutaneous allergic diseases such as
urticaria, latex allergy, and atopic dermatitis. Treatment of
these allergic diseases is usually performed with corticoster-
oids and antihistamines, but both of these drug classes have
limitations. Corticosteroids are powerful but relatively
nonspecific anti-inflammatory agents that sometimes cause
side effects such as increased susceptibility to infections.
Antihistamines antagonize several chemical mediators, but
severe symptoms are often resistant to these drugs. Therefore,
new therapeutic strategies for the allergic disorders are
required.
When patients with an IHR are challenged with an
allergen against which they are sensitized, they often develop
a biphasic immune reaction. Following allergen stimulation,
B cells differentiate into Ig-producing cells and secrete
allergen-specific IgE. Subsequent exposure to the allergen
induces activation of mast cells via crosslinking of high-
affinity IgE receptors bound to IgE with the allergen (Galli
et al., 2005). The activated mast cells release proinflamma-
tory vasoactive amines (e.g., histamine), arachidonic acid
derivatives (e.g., leukotriene (LT)C4), cytokines (e.g., tumor
necrosis factor-a (TNF-a)), and chemokines (e.g., regulated
on activation, normal T-cell expressed, and presumably
secreted (RANTES)) that produce a biphasic allergic reaction.
Thus, IgE production or mast cell activation is a key step in
development of the IHR, and suppression of these phenom-
ena may provide effective treatment of allergic diseases.
IL-21 is a 4-helix bundle type I cytokine that is produced
by activated CD4þ T cells (Parrish-Novak et al., 2000) and
natural killer T cells (Coquet et al., 2007), and shares the
common receptor g-chain with IL-2, IL-4, IL-7, IL-9, and IL-15
(Parrish-Novak et al., 2000). IL-21 has a wide variety of
functions, including regulation of activation, proliferation,
and differentiation of T cells, B cells, natural killer cells, and
dendritic cells (Brandt et al., 2007; Spolski and Leonard,
2008; Konforte et al., 2009). Interestingly, both the positive
and the negative regulatory effects of IL-21 on allergic
reactions have been reported. For example, administration of
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IL-21 during sensitization decreased eosinophil recruitment
into inflamed sites by inhibiting allergen-specific IgE produc-
tion in a mouse model of allergic airway inflammation
(Suto et al., 2002), whereas in IL-21 receptor-deficient mice,
allergen-induced eosinophil infiltration was reduced in the
inflamed airway (Fro¨hlich et al., 2007). Studies from our
laboratory have revealed that administration of IL-21 reduces
allergic reactions by suppressing production of allergen-
specific IgE or chemokines in mouse models of anaphy-
laxis (Kishida et al., 2007) and allergic rhinitis (Hiromura
et al., 2007). These findings suggest that exogenous IL-21
suppresses allergen-triggered immune responses by inhi-
biting allergen-specific IgE production, whereas the absence
of IL-21 receptor signaling reduces allergen-induced
inflammation.
The above observations prompted us to investigate the
potential suppressive effects of exogenous IL-21 on allergic
cutaneous inflammation. In this study, we investigated
the effects of IL-21 on the IHR in mouse skin during the
sensitization period and after completion of sensitization.
In addition, we evaluated the effects of IL-21 on allergen-
specific IgE production and mast cell degranulation as
possible mechanisms underlying IL-21-induced regulatory
effects in the cutaneous IHR.
RESULTS
IL-21 administration during sensitization reduces biphasic
allergic cutaneous reactions
Mice were sensitized intraperitoneally once with ovalbumin
(OVA) and given recombinant murine (rm)IL-21 or vehicle
twice a week for 2 weeks during the sensitization period, as
shown in Figure 1a. The sensitized mice were then
challenged with OVA and the time course of the ear swelling
response was assessed by measuring ear thickness and weight
as indices of edema and cell infiltration. The increase in ear
thickness was significant at 1 and 24 hours after allergen
challenge in control (IL-21-untreated allergic) mice. Admin-
istration of rmIL-21 during sensitization significantly
decreased the biphasic ear swelling response (Figure 2a). In
the controls, ear weight showed a large increase at 1 hour
after challenge and then decreased gradually. Administration
of rmIL-21 reduced the increase of ear weight at 1 and
24 hours after challenge (Figure 2b).
Histological examination of the ear skin revealed marked
edema in the dermis at 1 hour after challenge in control
mice, but only slight edema in IL-21-treated allergic mice
(Figure 2c). At 24 hours after challenge, leukocyte infiltration
in the dermis was also greatly decreased in IL-21-treated
allergic mice compared with controls (Figure 2c). To quantify
leukocyte infiltration into skin in the late phase, myeloper-
oxidase (MPO) and eosinophil peroxidase activities in the ear
skin were determined. In IL-21-treated allergic mice, these
activities were significantly lower than those in controls at
24 hours after challenge (Figure 2d). These results show that
rmIL-21 administration during the sensitization period
significantly reduces biphasic allergic cutaneous reactions.
IL-21 administration after completion of sensitization also
reduces biphasic allergic cutaneous reactions
Allergic patients are usually sensitized against one or more
allergens, as shown by the presence of specific IgE antibodies
to food and environmental allergens. Therefore, we examined
the effect of exogenous IL-21 on the IHR in skin after
completion of sensitization. Mice were sensitized intraper-
itoneally once with OVA, and completion of sensitization
was confirmed by measuring serum IgE levels 2 weeks later
(Supplementary Table S1 online). Mice were given rmIL-21 or
vehicle intraperitoneally for 4 consecutive days after comple-
tion of sensitization, as shown in Figure 1b. Interestingly,
rmIL-21 administration after completion of sensitization also
significantly suppressed the biphasic ear swelling responses
(Figure 3a). In addition, rmIL-21 greatly reduced the increase
in ear weight at 1 and 24 hours after challenge (Figure 3b).
Histological findings in ear skin following rmIL-21
administration showed only slight edema in the dermis in
the early phase, compared with control mice (Figure 3c). In
the late phase, leukocyte infiltration in rmIL-21-treated
allergic mice was significantly lower than that in control
mice (Figure 3c). MPO and eosinophil peroxidase activities
were also significantly reduced in rmIL-21-treated allergic
mice compared with controls (Figure 3d). These results
indicate that rmIL-21 administration after completion of
sensitization greatly suppressed biphasic allergic cutaneous
reactions.
To investigate the role of endogenous IL-21 in skin, we
examined expression of IL-21 in inflamed skin in the IHR and
the effects of neutralizing endogenous IL-21 in skin on the
IHR. Immunohistological analysis revealed no expression of
IL-21 in inflamed skin at 1 hour after challenge. In contrast,
IL-21 was weakly expressed in the dermis in the IHR at
24 hours (Supplementary Figure S1-a online). To investigate
Sensitization
Sensitization
Challenge
Challenge
0
0 17
Day
Day
rmIL-21 administration
rmIL-21 administration
7 14
14
Figure 1. Schemes showing the timing of sensitization, challenge, and
recombinant murine (rm)IL-21 administration. (a) Mice were sensitized by
intraperitoneal injection of ovalbumin (OVA) and given rmIL-21 or vehicle
intraperitoneally twice a week for 2 weeks during the sensitization period.
Reactions to OVA were elicited by intracutaneous injection of OVA in
the ear on day 14. (b) In separate experiments, mice were sensitized
by intraperitoneal injection of OVA and given rmIL-21 or vehicle
intraperitoneally once a day on days 14–17. Reactions to OVA were
elicited by intracutaneous injection of OVA in the ear at 2 hours after the
final rmIL-21 administration on day 17.
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the effects of anti-IL-21-neutralizing antibody treatment on
the IHR, sensitized mice were challenged by injecting
intradermally with OVA plus anti-IL-21-neutralizing antibody
or isotype-matched control IgG on day 14. Anti-IL-21
treatment resulted in no significant change in ear swelling
responses and histological findings compared with controls
(Supplementary Figure S1-b online).
Allergen-specific IgE production is suppressed by IL-21
administration during sensitization but not after completion
of sensitization
To investigate the mechanisms underlying IL-21-induced
regulation of allergic cutaneous reactions, we examined the
effects of rmIL-21 administration on serum IgE levels in the
mouse model of the cutaneous IHR. Mice were prepared as
shown in Figure 1 and serum levels of total IgE and OVA-
specific IgE at challenge were evaluated. Administration of
rmIL-21 during the sensitization period (Figure 1a) signifi-
cantly decreased the serum levels of total IgE and OVA-
specific IgE (Figure 4a). In contrast, rmIL-21 administration
after completion of sensitization (Figure 1b) did not affect the
amounts of total IgE and OVA-specific IgE (Figure 4b). These
results suggest that during sensitization rmIL-21 can suppress
the cutaneous IHR by inhibiting allergen-specific IgE produc-
tion, but that mechanisms underlying the regulatory effects of
rmIL-21 after completion of sensitization are not related to
allergen-specific IgE production.
To investigate the effects of IL-21 on B-cell function in the
mouse model of the cutaneous IHR, we examined expression
of the IL-21 receptor on splenic B cells and the effects of
in vitro IL-21 administration on IgE production by splenic B
cells. Flow cytometric analysis showed that splenic B cells
collected from OVA-sensitized mice expressed IL-21 receptor
on the cell surface (Supplementary Figure S2-a online).
Addition of rmIL-21 suppressed IgE production by splenic B
cells after culturing with IL-4 and lipopolysaccharide
(Supplementary Figure S2-b online). These in vitro data
are consistent with the effects on IgE production of in vivo
rmIL-21 administration during the sensitization period.
In vivo IL-21 administration after completion of sensitization
inhibits degranulation of mast cells in skin
To investigate the mechanisms underlying the regulatory
effect of IL-21 on the cutaneous IHR after completion of
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Figure 2. Effect on the cutaneous immediate hypersensitivity reaction (IHR)
of recombinant murine (rm)IL-21 administration during sensitization. Mice
were sensitized by intraperitoneal injection of ovalbumin (OVA) and given
rmIL-21 or vehicle intraperitoneally twice a week for 2 weeks during the
sensitization period. Reactions to OVA were elicited by intracutaneous
injection of OVA in the ear on day 14. Ear swelling responses were examined
by measuring the (a) thickness and (b) weight of the ears. (c) Histology of ear
skin was examined at 1 and 24 hours. Hematoxylin and eosin. Original
magnification  100, scale bar¼ 50mm. (d) Myeloperoxidase (MPO) and
eosinophil peroxidase (EPO) activities in skin tissue were examined at
24 hours. Data are expressed as means±SD of six mice per group. *Po0.01
versus vehicle administration in OVA-challenged mice. ##Po0.01 versus
corresponding sham-challenged mice.
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sensitization, we examined the effects of rmIL-21 on
degranulation of mast cells in skin. A histological examina-
tion with toluidine blue staining showed many degranulated
mast cells in the dermis in control mice at 1 hour after
challenge (Figure 5a). In contrast, there were few degranu-
lated mast cells in the dermis in rmIL-21-treated allergic
mice. The percentage of degranulated mast cells was
significantly lower in rmIL-21-treated allergic mice compared
with controls, whereas there was no difference in the total
number of dermal mast cells (Figure 5b). These results show
that rmIL-21 suppresses degranulation of mast cells in skin.
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* * Figure 3. Effect on the cutaneous immediate hypersensitivity reaction (IHR)
of recombinant murine (rm)IL-21 administration after sensitization.
Mice were sensitized by intraperitoneal injection of ovalbumin (OVA) and
then given rmIL-21 or vehicle intraperitoneally once a day on
days 14–17. Reactions to OVA were elicited by intracutaneous injection of
OVA in the ear after the final rmIL-21 administration on day 17. Ear swelling
responses were determined by the (a) ear thickness and (b) weight.
(c) Histology of ear skin was examined at 1 and 24 hours. Hematoxylin
and eosin. Original magnification  100, scale bar¼ 50 mm. (d)
Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) activities in skin
tissue were examined at 24 hours. Data are expressed as means±SD of six
mice per group. *Po0.01 versus vehicle in OVA-challenged mice. ##Po0.01
versus corresponding sham-challenged mice.
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Figure 4. Serum levels of allergen-specific IgE and total IgE. (a) Mice were
sensitized by intraperitoneal injection of ovalbumin (OVA) and given
recombinant murine (rm)IL-21 or vehicle intraperitoneally twice a week for 2
weeks during the sensitization period. Sera were collected on day 14. (b) In
separate experiments, mice were sensitized by intraperitoneal injection of
OVA and given rmIL-21 or vehicle intraperitoneally once a day on days
14–17. Sera were collected at 2 hours after the final rmIL-21 administration on
day 17. Serum levels of total IgE and OVA-specific IgE were measured using
the corresponding ELISA kits. Data are expressed as means±SD of six mice
per group. *Po0.01 versus vehicle in OVA-challenged mice. ##Po0.01
versus corresponding sham-sensitized mice.
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Recent reports have shown that IL-21 promotes CD8þ T-cell
responses (Moroz et al., 2004; Casey and Mescher, 2007).
Therefore, to investigate the effects of IL-21 on CD8þ T-cell
responses in the mouse model of the cutaneous IHR, we
performed CD8 staining in immunohistological analysis. The
number of CD8þ T cells in skin reduced in parallel to a
decrease in the total number of skin-infiltrating cells in rmIL-
21-treated allergic mice compared with controls at 24 hours
after challenge (Supplementary Table S2 online), suggesting
that the mechanism underlying the suppressive effects of
rmIL-21 after completion of sensitization is not related to
CD8þ T-cell responses.
In vitro IL-21 administration inhibits mediator release from
bone marrow-derived mast cells (BMMCs)
To investigate whether IL-21 directly affects degranulation of
mast cells, we examined the expression of the IL-21 receptor
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Figure 5. Effect of in vivo recombinant murine (rm)IL-21 administration on
mast cell degranulation. (a) Mice were sensitized by injecting ovalbumin
(OVA) intraperitoneally and given rmIL-21 or vehicle intraperitoneally once a
day on days 14–17. Reactions to OVA were elicited by intracutaneous
injection of OVA in the ear of mice at 2 hours after the final rmIL-21
administration on day 17. Ears were excised at 1 hour after challenge and
samples were stained with toluidine blue. Degranulated mast cells are
indicated by arrows. Original magnification  400, scale bar¼ 25mm.
(b) Dermal mast cells were evaluated by averaging the number of cells present
in 10 high-power fields. Data are expressed as means±SD of six mice per
group. *Po0.01 versus vehicle in OVA-challenged mice. #Po0.05 or
##Po0.01 versus corresponding sham-challenged mice.
R
el
at
ive
 c
e
ll 
co
un
t
100 101 102 103 104
IL-21 receptor
Vehicle
IL-21
20
20
30
40
15
* *
*
* * *
10
10
H
is
ta
m
in
e 
re
le
as
e
(%
 of
 to
tal
)
LT
C 4
 
re
le
as
e
(ng
 m
l–1
)
TN
F-
α
 
re
le
as
e
(ng
 m
l–1
)
R
AN
TE
S 
re
le
as
e
(ng
 m
l–1
)
5
0
0
0
0
0.2
0.4
0.6
0.8
0.5
1
1.5
2
0 0.5
Time after challenge (hours)
Time after challenge (hours)
12 24
0 0.5 12 24
Time after challenge (hours)
0 0.5 12 24
Time after challenge (hours)
0 0.5
*
* *
*
12 24
Figure 6. Effect of in vitro recombinant murine (rm)IL-21 administration on
mediator release from mast cells. (a) Bone marrow-derived mast cells
(BMMCs) were labeled by a specific antibody to IL-21 receptor and then IL-21
receptor expression on the surface of BMMCs was analyzed by FACS.
Representative data from one of three independent experiments are shown.
(b) In separate experiments, BMMCs were sensitized with anti-dinitrophenyl
(DNP) IgE, incubated in the presence of rmIL-21 or vehicle, and then
challenged with DNP-bovine serum albumin for 0, 0.5, 12, and 24 hours.
Histamine, leukotriene (LT)C4, tumor necrosis factor-a (TNF-a), and RANTES
(regulated on activation, normal T-cell expressed, and presumably secreted)
levels were quantified in cell-free supernatants using the corresponding ELISA
kits (n¼ 3–5 in each group). *Po0.01 versus vehicle at the same time point
after challenge.
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on murine mast cells and the effects of in vitro IL-21
administration on mediator release from mast cells. BMMCs
were generated by culturing bone marrow cells from BALB/c
mice in the presence of IL-3. After 4 weeks of culture, 498%
of the cells were identifiable as mast cells by morphological
analysis with Giemsa staining and by FACS analysis of cell
surface expression of c-Kit (data not shown). Flow cytometric
analysis showed that BMMCs expressed IL-21 receptor on the
cell surface (Figure 6a). Next, to investigate the direct effect of
IL-21 on mediator release from murine mast cells, BMMCs
were sensitized with monoclonal anti-dinitrophenyl
IgE antibody, incubated in the presence of rmIL-21, and
challenged with dinitrophenyl-bovine serum albumin. Mea-
surement of mediator levels in cell-free supernatants showed
that rmIL-21 suppressed the release of histamine and LTC4 at
0.5, 12, and 24 hours and of TNF-a and RANTES at 12 and
24 hours from BMMCs (Figure 6b). To confirm the suppres-
sive effects of IL-21 on mediator release from mast cells, anti-
IL-21-neutralizing antibody was added to the culture medium
of BMMCs before addition of rmIL-21. Anti-IL-21 treatment
inhibited the suppressive effects of IL-21 on mediator release
from mast cells (Supplementary Figure S3 online). These
results indicate that IL-21 directly suppresses mediator release
from murine mast cells. We next investigated whether IL-21
also affects non-IgE-mediated mast cell activation. Addition
of rmIL-21 did not affect the release of mediators from
phorbol 12-myristate 13-acetate/ionomycin-stimulated mast
cells (Supplementary Figure S4 online), suggesting that
the regulatory effect of IL-21 is restricted to IgE-mediated
mast cell activation.
DISCUSSION
This study showed a, to our knowledge, previously un-
reported function of IL-21 in the cutaneous IHR in the mice.
Intraperitoneal administration of rmIL-21 during the sensiti-
zation period or after completion of sensitization significantly
suppressed the cutaneous IHR. Interestingly, the mechanisms
of these suppressive effects of IL-21 differed depending on
the timing of rmIL-21 administration. Thus, administration of
rmIL-21 after completion of sensitization suppressed mast
cell degranulation in skin, whereas administration of this
cytokine during sensitization inhibited allergen-specific
IgE production.
Our in vitro results suggest that exogenous IL-21 directly
suppresses IgE-mediated activation of murine mast cells. The
mediators released immediately after mast cell activation
such as histamine and LTs have been revealed to be
important in induction of vascular permeability changes,
leading to a rapid increase in capillary permeability and
edema formation (the early-phase reaction) (Galli et al.,
2005). In contrast, the mast cell-derived cytokines such as
IL-4, IL-5, and TNF-a and chemokines such as RANTES
develop an influx of inflammatory cells (the late-phase
reaction) (Galli et al., 2005). On activation, mast cells not
only attract inflammatory cells by secreting chemotactic
factors, but also induce maturation of Langerhans cells and
dendritic cells that are localized with mast cells in atopic
dermatitis lesions (Jawdat et al., 2004; Kitawaki et al., 2006).
Activated mast cells also present antigens to T cells as
antigen-presenting cells by expressing major histocompat-
ibility complex molecules (Mekori and Metcalfe, 1999; Henz
et al., 2001), and directly induce IgE synthesis via CD40/
CD40 ligand interactions with B cells (Gauchat et al., 1993).
Therefore, IL-21 may exert its powerful effects on allergic skin
inflammation by inhibiting these reactions via suppression of
mast cell activation. The signaling pathways mediated by
IL-21 in mast cells remain unclear. Therefore, further studies
are required to address the mechanisms of the regulatory
effects of IL-21 on IgE-mediated mast cell activation.
Our data also suggest that IL-21 administration during the
sensitization period has an inhibitory effect on allergen-
specific IgE production. These results are consistent with our
previous findings in a mouse model of anaphylaxis (Kishida
et al., 2007). Regulation of IgE production by B cells differs
in humans and mice. In experimental mouse models, a
regulatory role of IL-21 on IgE production has been reported:
exogenous IL-21 administration to mice was found to
suppress allergen-specific IgE production by inhibiting IgE
class switch recombination (Suto et al., 2002; Hiromura
et al., 2007; Kishida et al., 2007), whereas mice deficient in
the IL-21 receptor have increased IgE levels (Ozaki et al.,
2002). In contrast, the positive effects of human IL-21 on IgE
production by human B cells stimulated with anti-CD40 plus
IL-4 have been shown (Ettinger et al., 2005; Pene et al.,
2006). It has also been reported that IL-21 induces apoptosis
of murine B cells, including IgE-bearing B cells, in vitro
(Mehta et al., 2003; Jin et al., 2004; Konforte et al., 2009).
Taken together, these findings suggest that IL-21 suppresses
allergen-specific IgE production by inhibiting IgE class switch
recombination and/or by inducing apoptosis of B cells in
mice. In this study, rmIL-21 administration after completion
of sensitization did not reduce serum levels of allergen-
specific IgE. Because the half-life of murine IgE in serum is
relatively short (5–12 hours) (Haba et al., 1985; Vieira and
Rajewsky, 1988), IgE production may not be inhibited by
IL-21 after generation of IgE-producing B cells. Because IL-21
induces apoptosis of B cells through nonspecific stimulation
via B-cell receptors or strong signals via Toll-like receptors
(Konforte et al., 2009), this cytokine may fail to affect the
survival of existing IgE-producing B cells under the experi-
mental conditions in the study.
We note that there are conflicting data on the effects of
IL-21 on allergic skin inflammation. It has been reported that
IL-21-treated dendritic cells fail to induce hapten-induced
contact hypersensitivity reactions via inhibition of dendritic
cell activation and maturation in vivo (Brandt et al., 2003). In
contrast, IL-21 receptor deficiency inhibited allergic cuta-
neous inflammation by suppressing trafficking of cutaneous
dendritic cells to draining lymph nodes in a murine model of
epicutaneous sensitization using tape stripping (Jin et al.,
2009). In this study, we showed that exogenous IL-21
administration suppressed the cutaneous IHR, whereas
anti-IL-21-neutralizing antibody treatment did not influence
the cutaneous reaction. In addition, we found that exogenous
IL-21 administration did not affect chronic dermatitis in
another murine model of repeated hapten epicutaneous
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application (Tamagawa-Mineoka et al., unpublished data).
These studies used a variety of allergic cutaneous inflamma-
tion protocols, and the effects of IL-21 on allergic dermatitis
in vivo may differ depending on the inflammatory conditions
of the experiments. Therefore, further studies of the various
mechanisms underlying the effects of IL-21 on allergic
cutaneous inflammation are required before possible clinical
use of this cytokine.
In conclusion, this study revealed the in vivo effects
of exogenous IL-21 on the cutaneous IHR. Administration of
rmIL-21 during sensitization inhibited the cutaneous IHR by
regulating allergen-specific IgE production, whereas rmIL-21
given after completion of sensitization suppressed mast cell
degranulation in skin. Therefore, IL-21 may have potential for
treatment of allergic cutaneous diseases.
MATERIALS AND METHODS
Mice
Male BALB/c mice were purchased from Shimizu Laboratory
Supplies (Kyoto, Japan) and used at age 6–8 weeks. The experimental
procedure was approved by the committee for animal research,
Kyoto Prefectural University of Medicine.
Sensitization
The biphasic allergic murine skin model was prepared as described
previously (Sawada et al., 1997; Tamagawa-Mineoka et al., 2009).
Mice were sensitized by intraperitoneal injection of 3 mg OVA (grade
V; Sigma-Aldrich, St Louis, MO) and 4 mg aluminum hydroxide
(Pierce, Rockford, IL). Reactions to OVA were elicited by intracu-
taneous injection of 10 mg OVA in the right ear of mice on day
14 (Figure 1a) or day 17 (Figure 1b), with the same volume of vehicle
injected into the left ear as a control.
IL-21 administration
Groups of mice were injected intraperitoneally with rmIL-21 (0.5mg
per mouse; R&D Systems, Minneapolis, MN) or vehicle as a control
twice a week for 2 weeks during the sensitization period, with
the first injection being performed 2 hours before injection of OVA
for sensitization (Figure 1a). In separate experiments, groups of mice
were given rmIL-21 (0.5 mg per mouse) or vehicle intraperitoneally
once a day on days 14–17, with the final injection being performed
2 hours before OVA challenge (Figure 1b).
Histological examination
Ears were excised at 1 and 24 hours after challenge. Samples were fixed
with 10% formalin and embedded in paraffin. Sections (5mm) were cut
using a microtome and stained with hematoxylin and eosin for general
histological evaluation and toluidine blue for mast cell staining.
Measurement of MPO and eosinophil peroxidase activities
Ear tissue was homogenized and MPO activity was measured using
an MPO assay kit (CytoStore, Calgary, Alberta, Canada) with
absorbance measured at 450 nm. Eosinophil peroxidase activity
was measured based on absorbance at 490 nm after incubation
of a homogenate of ear tissue (50 ml) with 100ml of 50 mmol l–1
Tris-buffered saline containing 0.1% Triton X-100, 1 mmol l–1
o-phenylenediamine, and 500mmol l–1 hydrogen peroxide, as
previously described (Kawase et al., 2003).
Measurement of serum IgE
Sera were collected on day 14 in both protocols shown in Figure 1
and at 2 hours after the final administration of rmIL-21 on day 17 in
the protocol shown in Figure 1b. Serum levels of total IgE and
OVA-specific IgE were evaluated using the corresponding ELISA kits
purchased from BD PharMingen (San Diego, CA) and Dainippon
Sumitomo Pharma (Osaka, Japan), respectively.
Preparation of BMMCs
BMMCs were generated from femoral bone marrow cells of male BALB/
c mice using a previously described method (Nakano et al., 1985) with
slight modifications. Bone marrow cells were cultured in RPMI-1640
(GIBCO, Grand Island, NY) supplemented with 10% heat-inactivated
fetal calf serum, 100 U ml–1 penicillin, 100mg ml–1 streptomycin, 100mM
2-mercaptoethanol, 1 mM sodium pyruvate, 0.1 mM minimal essential
medium with nonessential amino acid solution, and 10 ng ml–1 rmIL-3
(Peprotech, Rocky Hill, NJ) at 37 1C for 4 weeks.
Flow cytometry
Cells were incubated with rat anti-mouse IL-21 receptor antibody
(clone 155516; R&D Systems) for 30 minutes at 4 1C. After washing,
the samples were incubated with secondary FITC-labeled goat
anti-rat IgG. Following further washing, the cells were analyzed by
FACS (Becton Dickinson, San Jose, CA). Phycoerythrin-labeled rat
anti-mouse CD117 antibody (clone 180627; R&D Systems) was used
in FACS analysis of c-Kit expression on BMMCs.
Stimulation of BMMCs
BMMCs were stimulated using a previously described method
(Malaviya and Uckun, 2002) with slight modifications. BMMCs were
sensitized with monoclonal anti-dinitrophenyl IgE antibody
(0.24 mg ml–1; clone SPE-7; Sigma-Aldrich) overnight at 37 1C. Un-
bound IgE was removed by washing the cells twice with phosphate-
buffered saline. After washing, the BMMCs were resuspended in RPMI-
1640 at a cell density of 1 106 per ml and cultivated for 60 minutes in
the presence of 40 ng ml–1 rmIL-21. The cells were then challenged
with 20 ng ml–1 dinitrophenyl-bovine serum albumin (LSL, Tokyo,
Japan) for 0, 0.5, 12, and 24 hours at 37 1C.
Mediator release assays
Quantitative determination of histamine, LTC4, TNF-a, and RANTES
in cell-free supernatants was performed with a histamine enzyme
immunoassay kit (SPI-BIO, Bretonneux, France), mouse LTC4 ELISA
kit (Cusabio Biotech, Newark, DE), mouse TNF-a ELISA kit (Abnova,
Taoyuan, Taiwan), and mouse RANTES ELISA kit (Peprotech),
respectively.
Statistical analysis
Data from all studies are expressed as means±SD. Statistical
significance was assessed by one-way analysis of variance followed
by Tukey’s multiple comparison test. Student’s t-test was used for
comparison of mediator release from BMMCs. A P-value of o0.05
was considered significant.
Complete Materials and Methods and associated references are
available in the Supplementary Information online.
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